Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol® in Renal Transplantation) study design and baseline data

Journal of Cardiovascular Risk

Volumn 8, Issue 2, 2001, Pages 63-71

  Holdaas, H ^a   Fellstrom B ^a   Holme, I ^a   Nyberg, G ^a   Fauchald, P ^a   Jardine, A ^a   Gronhagen Riska C ^a   Madsen, S ^a   Neumayer, H H ^a   Cole, E ^a   Maes, B ^a   Weinreich, T ^a   Olsson, A G ^a   Pedersen, T R ^a   Benghozi, R ^a   Hartmann, A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular disease; Fluvastatin; HMG CoA reductase inhibitor; Hyperlipidaemia; Major adverse cardiac events; Mortality; Renal transplant

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; STATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 17744364899     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043798-200104000-00002     Document Type: Article

References (31)

1. Cardiovascular morbidity and mortality in renal transplant recipients. Results from a 5 year follow-up
2. Hypertension and ischaemic heart disease in renal transplant recipients
3. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. The prevalence of hyperlipidemia in renal transplant recipients
10. Lipid abnormalities in renal disease
11. Atherosclerosis and lipid disorders after renal transplantation
12. Hyperlipidaemia in renal transplantation - Risk factor for long-term graft outcome
13. Lipid abnormalities in cyclosporine-prednisolone-treated renal transplant recipients
14. Epidemiology of cardiovascular risk factors in chronic renal disease
15. Hyperlipidaemia in solid organ transplantation
16. Impact of serum lipids on long-term graft and patient survival after renal transplantation
17. Is dietary intervention effective in post-transplant hyperlipidaemia?
18. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation
19. The effects of pravastatin on hyperlipidaemia in renal transplant recipients
20. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine
21. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine
22. Hyperlipidemia in renal transplant patients: Does it matter and can we treat it
23. Cardiovascular disease after renal transplantation
24. Cardiovascular complications after renal transplantation
25. No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure
26. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial
27. The effect of fluvastatin on cardiac events in patients with syptomatic coronary artery disease during one year of treatment
28. Cholesterol reduction yields clinical benefit: Impact of statin trials
29. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection?
30. Clinical validation and reproducibility of the Banff Schema for renal allograft pathology